These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11449333)

  • 21. Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa.
    Ellgaard TW; Bindslev L; Kamstrup S
    Protein Expr Purif; 2017 Jan; 129():94-100. PubMed ID: 27620499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced production of recombinant B-domain deleted factor VIII from Chinese hamster ovary cells by propionic and butyric acids.
    Chun BH; Park SY; Chung N; Bang WG
    Biotechnol Lett; 2003 Feb; 25(4):315-9. PubMed ID: 12882544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system.
    Orlova NA; Kovnir SV; Gabibov AG; Vorobiev II
    BMC Biotechnol; 2017 Mar; 17(1):33. PubMed ID: 28340620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
    Lee DC; Miller JL; Petteway SR
    Haemophilia; 2002 Mar; 8 Suppl 2():6-9. PubMed ID: 11966845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.
    Lind P; Larsson K; Spira J; Sydow-Bäckman M; Almstedt A; Gray E; Sandberg H
    Eur J Biochem; 1995 Aug; 232(1):19-27. PubMed ID: 7556150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
    Oh HK; Lee JM; Byun TH; Park SY; Kim YH
    Biotechnol Prog; 2001; 17(6):1119-27. PubMed ID: 11735450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics.
    Adamson SR
    Dev Biol Stand; 1998; 93():89-96. PubMed ID: 9737383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
    Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients.
    Rothschild C; Scharrer I; Brackmann HH; Stieltjes N; Vicariot M; Torchet MF; Effenberger W
    Haemophilia; 2002 Mar; 8 Suppl 2():10-4. PubMed ID: 11966846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparability studies of new 3rd generation recombinant human factor VIII GreenGene F after improvement of formulation and viral inactivation/removal process.
    Paik SH; Kim YJ; Han SK; Kim JY; Park H; Park YI
    Biologicals; 2012 Nov; 40(6):405-14. PubMed ID: 23058573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of a B-domain deleted factor VIII gene in a human hepatic cell line.
    Herlitschka SE; Schlokat U; Falkner FG; Dorner F
    J Biotechnol; 1998 May; 61(3):165-73. PubMed ID: 9684335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
    Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
    Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of wet pasteurization of a factor VIII concentrate produced by controlled-pore silica adsorption.
    Hiemstra H; Nieuweboer CE; Idoe MA; Claassen JE; Vos AH; Tersmette M; Strengers PF; Over J; Mauser-Bunschoten EP; Heijboer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):557-63. PubMed ID: 1714860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients.
    Courter SG; Bedrosian CL
    Semin Hematol; 2001 Apr; 38(2 Suppl 4):52-9. PubMed ID: 11449336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.
    McCue J; Kshirsagar R; Selvitelli K; Lu Q; Zhang M; Mei B; Peters R; Pierce GF; Dumont J; Raso S; Reichert H
    Biologicals; 2015 Jul; 43(4):213-9. PubMed ID: 26094124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An improved manufacturing process for Xyntha/ReFacto AF.
    Kelley B; Jankowski M; Booth J
    Haemophilia; 2010 Sep; 16(5):717-25. PubMed ID: 20041957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.
    Windyga J; Rusen L; Gruppo R; O'Brien AC; Kelly P; Roth DA; Arkin S
    Haemophilia; 2010 Sep; 16(5):731-9. PubMed ID: 20412322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.
    Farrugia A
    Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.